Indication
Ovarian Serous Tumor
6 clinical trials
6 products
6 drugs
Clinical trial
Phase 2 Study of M6620 (VX-970) in Combination With Gemcitabine Versus Gemcitabine Alone in Subjects With Platinum-Resistant Recurrent Ovarian or Primary Peritoneal Fallopian Tube CancerStatus: Active (not recruiting), Estimated PCD: 2020-06-15
Product
BerzosertibDrug
GemcitabineClinical trial
Upfront Systematic Tumour BRCA Testing in Patients With High Grade Serous or Endometrioid Ovarian, Fallopian Tube or Primary Peritoneal Cancer: The t-BRCA StudyStatus: Active (not recruiting), Estimated PCD: 2025-11-01
Clinical trial
Phase II Study to Assess the Efficacy of Niraparib Rechallenge After Surgery in Ovarian Cancer Patients With Oligometastatic Progression (The ANALLISA Study)Status: Not yet recruiting, Estimated PCD: 2025-10-01
Product
NiraparibClinical trial
Phase II Trial to Evaluate the Efficacy of Auranofin and Sirolimus in Serous Ovarian Cancer Patients With Recurrent DiseaseStatus: Active (not recruiting), Estimated PCD: 2019-07-31
Product
AuranofinDrug
sirolimusClinical trial
A Phase III Study Comparing Single-Agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-Based Chemotherapy in Women With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal CancerStatus: Active (not recruiting), Estimated PCD: 2020-02-23
Drug
AN0025Product
CediranibDrug
olaparibDrug
TiragolumabClinical trial
An Open-label, Single Arm, Prospective, Multi-center, Tandem Two Stage Designed, Phase II Study to Evaluate the Efficacy of Fulvestrant in Women With Recurrent/Metastatic Estrogen Receptor Positive Gynecological MalignanciesStatus: Completed, Estimated PCD: 2022-04-01
Drug
Alpelisib